Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study.
Anti-melanoma differentiation-associated gene 5 antibody
Dermatomyositis
HRCT score
Quantitative CT analysis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
21
09
2021
accepted:
18
12
2021
revised:
16
12
2021
pubmed:
17
1
2022
medline:
4
5
2022
entrez:
16
1
2022
Statut:
ppublish
Résumé
This study aimed to assess the utility of quantitative high-resolution computed tomography (HRCT) for determining the clinical course of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease (MDA5 This study retrospectively analyzed the data of 34 patients with MDA5 Thirty-four patients underwent follow-up CT scans 35 (range: 14-78) days after diagnosis. Patients who died of rapidly progressive ILD had higher LSS (p < 0.01), percentage of opacity (p < 0.01), percentage of high opacity (p = 0.01), total ground-glass opacity score (p = 0.01), serum C-reactive protein (CRP) (p = 0.03), and alveolar-arterial oxygen difference (Aa-DO2) (p = 0.01) at follow-up than those who survived. Quantified HRCT scores correlated with serum CRP and Aa-DO2 levels at follow-up. LSS at follow-up (AUC = 0.844, p < 0.01) was the best predictor of death in MDA5 Quantitative CT analysis of MDA5
Identifiants
pubmed: 35034225
doi: 10.1007/s10067-021-06033-7
pii: 10.1007/s10067-021-06033-7
doi:
Substances chimiques
Autoantibodies
0
Interferon-Induced Helicase, IFIH1
EC 3.6.4.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1473-1481Informations de copyright
© 2022. International League of Associations for Rheumatology (ILAR).
Références
Sato S, Murakami A, Kuwajima A et al (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11:e0154285
doi: 10.1371/journal.pone.0154285
Fujiki Y, Kotani T, Isoda K et al (2018) Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol 28:133–140
doi: 10.1080/14397595.2017.1318468
Cao H, Pan M, Kang Y et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti–melanoma differentiation–associated gene 5 antibody. Arthritis Care Res 64:1602–1610
doi: 10.1002/acr.21728
Zou J, Guo Q, Chi J, Wu H, Bao C (2015) HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin Rheumatol 34:707–714
doi: 10.1007/s10067-015-2866-5
Ufuk F, Demirci M, Altinisik G (2020) Quantitative computed tomography assessment for systemic sclerosis–related interstitial lung disease: comparison of different methods. Eur Radiol 1–12
Ariani A, Aiello M, Silva M et al (2017) Quantitative CT indexes are significantly associated with exercise oxygen desaturation in interstitial lung disease related to systemic sclerosis. Clin Respir J 11:983–989
doi: 10.1111/crj.12451
Chen A, Karwoski RA, Gierada DS, Bartholmai BJ, Koo CW (2020) Quantitative CT analysis of diffuse lung disease. Radiographics 40:28–43
doi: 10.1148/rg.2020190099
Chassagnon G, Vakalopoulou M, Régent A et al (2020) Deep learning–based approach for automated assessment of interstitial lung disease in systemic sclerosis on CT images. Radiol Artif Intell 2:e190006
doi: 10.1148/ryai.2020190006
Zhu J, Shen B, Abbasi A, Hoshmand-Kochi M, Li H, Duong TQ (2020) Deep transfer learning artificial intelligence accurately stages COVID-19 lung disease severity on portable chest radiographs. PloS One 15:e0236621
doi: 10.1371/journal.pone.0236621
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:344–347
doi: 10.1056/NEJM197502132920706
Sontheimer RD (2002) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20:387–408
doi: 10.1016/S0733-8635(02)00021-9
Muro Y, Sugiura K, Akiyama M (2013) Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol 32:395–398
doi: 10.1007/s10067-012-2142-x
Gono T, Okazaki Y, Murakami A, Kuwana M (2019) Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Mod Rheumatol 29:140–145
doi: 10.1080/14397595.2018.1452179
Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R (2016) Anti–melanoma differentiation–associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with Amyopathic and Myopathic dermatomyositis. Arthritis Care Res 68:689–694
doi: 10.1002/acr.22728
Matsushita T, Mizumaki K, Kano M et al (2017) Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol 176:395–402
doi: 10.1111/bjd.14882
Kameda H, Nagasawa H, Ogawa H et al (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32:1719–1726
pubmed: 16142867
Nakashima R, Mimori T (2013) Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi 36:71–76
doi: 10.2177/jsci.36.71
Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51:1563–1570
doi: 10.1093/rheumatology/kes102
Tanizawa K, Handa T, Nakashima R et al (2013) The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 107:745–752
doi: 10.1016/j.rmed.2013.01.014
Suzuki Y, Hayakawa H, Miwa S et al (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:201–206
doi: 10.1007/s00408-009-9146-6
Andersson H, Sem M, Lund MB et al (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 54:1420–1428
doi: 10.1093/rheumatology/kev004
Shirakashi M, Nakashima R, Tsuji H et al (2020) Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology 59:3284–3292
doi: 10.1093/rheumatology/keaa123
Yamaguchi K, Yamaguchi A, Kashiwagi C et al (2018) Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respir Med 140:1–5
doi: 10.1016/j.rmed.2018.05.010
Koichi Y, Aya Y, Megumi U et al (2017) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 27:536–540
doi: 10.3109/14397595.2015.1014140
Yamaguchi K, Yamaguchi A, Itai M et al (2019) Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 1–8
Si M, Fujiwara C, Sekiguchi A et al (2019) Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol 46:213–218
doi: 10.1111/1346-8138.14758
Motegi S, Sekiguchi A, Toki S et al (2019) Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol
Yamaguchi K, Yamaguchi A, Onuki Y et al (2021) Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age. Mod Rheumatol 31:177–185
doi: 10.1080/14397595.2020.1740400
Sekiguchi A, Inoue Y, Yamazaki S et al (2020) Demographic and clinical characteristics of cytomegalovirus reactivation in dermatomyositis. J Dermatol 47:876–881
doi: 10.1111/1346-8138.15409
Tanizawa K, Handa T, Nakashima R et al (2011) HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105:1380–1387
doi: 10.1016/j.rmed.2011.05.006
Kazerooni EA, Martinez FJ, Flint A et al (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 169:977–983
doi: 10.2214/ajr.169.4.9308447
Goldin JG, Kim GHJ, Tseng C-H et al (2018) Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc 15:1286–1295
doi: 10.1513/AnnalsATS.201802-079OC
Guisado-Vasco P, Silva M, Duarte-Millán MA et al (2019) Quantitative assessment of interstitial lung disease in Sjögren’s syndrome. PloS One 14:e0224772
doi: 10.1371/journal.pone.0224772
Gono T, Masui K, Nishina N et al (2021) Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis/dermatomyositis–associated interstitial lung disease. Arthritis Rheumatol 73:677–686
doi: 10.1002/art.41566
Sato S, Masui K, Nishina N et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology 57:1212–1221
doi: 10.1093/rheumatology/key060
Tsuji H, Nakashima R, Hosono Y et al (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti–melanoma differentiation–associated gene 5–positive dermatomyositis. Arthritis Rheumatol 72:488–498
doi: 10.1002/art.41105
So H, Wong VTL, Lao VWN, Pang HT, Yip RML (2018) Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol 37:1983–1989
doi: 10.1007/s10067-018-4122-2
Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis–associated interstitial lung disease. N Engl J Med 381:291–293
doi: 10.1056/NEJMc1900045